SCHEMBL26640202

SCHEMBL26640202

CN1CCc2ccc(Nc3ncc4c(n3)CN(C(=O)OC(C)(C)C)CC4)cc2CC1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.62
▸ PTK2 Q05397 7/20 0.49
▸ JAK2 O60674 6/20 0.49
▸ JAK3 P52333 6/20 0.49
▸ IGF1R P08069 1/20 0.49
▸ ESR2 Q92731 1/20 0.48
▸ NR1H2 P55055 1/20 0.47
▸ WEE1 P30291 3/20 0.46
▸ PDGFRB P09619 1/20 0.46
▸ DDB1 Q16531 1/20 0.45
▸ CRBN Q96SW2 1/20 0.45
▸ ULK1 O75385 1/20 0.45
▸ ULK2 Q8IYT8 1/20 0.45
▸ CDK2 P24941 2/20 0.45
▸ MAPK1 P28482 2/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26640456 0.94 MAPT (0.64) MAPTPTK2JAK2JAK3IGF1R
SCHEMBL27053860 0.90 MAPT (0.60) MAPTPTK2JAK2JAK3IGF1R
SCHEMBL26640600 0.89 MAPT (0.61) MAPTPTK2JAK2JAK3IGF1R
SCHEMBL30648622 0.89 MAPT (0.61) MAPTPTK2JAK2JAK3IGF1R
SCHEMBL26640585 0.89 MAPT (0.61) MAPTPTK2JAK2JAK3IGF1R
SCHEMBL27054345 0.89 MAPT (0.56) MAPTPTK2JAK2JAK3IGF1R
SCHEMBL26640513 0.88 MAPT (0.58) MAPTPTK2JAK2JAK3IGF1R
SCHEMBL26640159 0.87 MAPT (0.59) MAPTPTK2JAK2JAK3IGF1R
SCHEMBL26640167 0.86 MAPT (0.64) MAPTPTK2JAK2JAK3IGF1R
SCHEMBL26640303 0.86 MAPT (0.57) MAPTPTK2JAK2JAK3IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 — — EP disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS MERCK HEALTHCARE KGAA (DE) 2024-01-25 — — US disclosed
WO-2023220541-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS MERCK PATENT GMBH (DE) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025922-A1 TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS PDXK, DTYMK, HIPK1 MAPT 3283/4885PTK2 1166/4885JAK2 1595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback